Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology
May 02, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, May 02, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today...
Nuwellis Announces Closing of $2.7 Million Public Offering
April 30, 2024 18:09 ET
|
Nuwellis, Inc.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024
April 30, 2024 16:41 ET
|
Nuwellis, Inc.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it...
Nuwellis Announces Pricing of $2.7 Million Public Offering
April 26, 2024 09:17 ET
|
Nuwellis, Inc.
MINNEAPOLIS, April 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid...
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
April 09, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, April 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration...
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
March 07, 2024 09:08 ET
|
Nuwellis, Inc.
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial...
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, March 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial...
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
February 27, 2024 09:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it...
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
February 22, 2024 07:58 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its...
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2024 17:06 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective February 20, 2024, the Company’s independent directors approved equity awards under...